These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 9428836)

  • 1. Costs of acid-related disorders to a health maintenance organization.
    Levin TR; Schmittdiel JA; Kunz K; Henning JM; Henke CJ; Colby CJ; Selby JV
    Am J Med; 1997 Dec; 103(6):520-8. PubMed ID: 9428836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Work loss costs due to peptic ulcer disease and gastroesophageal reflux disease in a health maintenance organization.
    Henke CJ; Levin TR; Henning JM; Potter LP
    Am J Gastroenterol; 2000 Mar; 95(3):788-92. PubMed ID: 10710076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A cost analysis of a Helicobacter pylori eradication strategy in a large health maintenance organization.
    Levin TR; Schmittdiel JA; Henning JM; Kunz K; Henke CJ; Colby CJ; Selby JV
    Am J Gastroenterol; 1998 May; 93(5):743-7. PubMed ID: 9625120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The economic impact of GERD and PUD: examination of direct and indirect costs using a large integrated employer claims database.
    Joish VN; Donaldson G; Stockdale W; Oderda GM; Crawley J; Sasane R; Joshua-Gotlib S; Brixner DI
    Curr Med Res Opin; 2005 Apr; 21(4):535-44. PubMed ID: 15899102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cost of gastro-oesophageal reflux disease, dyspepsia and peptic ulcer disease in Sweden.
    Agréus L; Borgquist L
    Pharmacoeconomics; 2002; 20(5):347-55. PubMed ID: 11994044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic acid-related disorders are common and underinvestigated.
    Majumdar SR; Soumerai SB; Farraye FA; Lee M; Kemp JA; Henning JM; Schrammel P; LeCates RF; Ross-Degnan D
    Am J Gastroenterol; 2003 Nov; 98(11):2409-14. PubMed ID: 14638341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic burden of gastro-oesophageal reflux disease and dyspepsia: A community-based study.
    Moghimi-Dehkordi B; Vahedi M; Khoshkrood Mansoori B; Kasaeian A; Safaee A; Habibi M; Pourhoseingholi A; Pourhoseingholi MA; Zali MR
    Arab J Gastroenterol; 2011 Jun; 12(2):86-9. PubMed ID: 21684479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of a Helicobacter pylori treatment strategy on health care expenditures in patients with peptic ulcer disease and dyspepsia.
    Kearney DJ; Liu CF; Crump C; Brousal A
    Am J Gastroenterol; 2003 Sep; 98(9):1952-62. PubMed ID: 14499771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The risk factors and quality of life in patients with overlapping functional dyspepsia or peptic ulcer disease with gastroesophageal reflux disease.
    Lee SW; Lee TY; Lien HC; Yeh HZ; Chang CS; Ko CW
    Gut Liver; 2014 Mar; 8(2):160-4. PubMed ID: 24672657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Formulary management of antiulcer drugs: economic considerations.
    Tucker PP; Nash DB
    Pharmacoeconomics; 1994 Apr; 5(4):313-34. PubMed ID: 10147240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Costs of care for irritable bowel syndrome patients in a health maintenance organization.
    Levy RL; Von Korff M; Whitehead WE; Stang P; Saunders K; Jhingran P; Barghout V; Feld AD
    Am J Gastroenterol; 2001 Nov; 96(11):3122-9. PubMed ID: 11721759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cost of enhanced acid suppression.
    Erstad BL
    Pharmacotherapy; 2003 Oct; 23(10 Pt 2):94S-100S. PubMed ID: 14587964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gastro-oesophageal acid-related disease, co-morbidity and medical care cost.
    Jayadevappa R; Chhatre S; Weiner M
    Chronic Illn; 2008 Sep; 4(3):209-18. PubMed ID: 18796510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eradicating Helicobacter pylori in peptic ulcer disease reduces medical costs in the community.
    Sone Y; Kumada T; Toyoda H; Yokoyama M; Kato M; Asaka M
    Helicobacter; 2008 Oct; 13(5):346-51. PubMed ID: 19250509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pharmacoeconomics of dyspesia and peptic ulcer disease].
    Kusowska J
    Pol Merkur Lekarski; 2006 Jan; 20(115):125-8. PubMed ID: 16617753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized controlled trial of test-and-treat strategy for Helicobacter pylori: clinical outcomes and health care costs in a managed care population receiving long-term acid suppression therapy for physician-diagnosed peptic ulcer disease.
    Allison JE; Hurley LB; Hiatt RA; Levin TR; Ackerson LM; Lieu TA
    Arch Intern Med; 2003 May; 163(10):1165-71. PubMed ID: 12767952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of dyspepsia, heartburn, and peptic ulcer disease in veterans.
    Dominitz JA; Provenzale D
    Am J Gastroenterol; 1999 Aug; 94(8):2086-93. PubMed ID: 10445532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A cost analysis of gastro-oesophageal reflux disease and dyspepsia in Iran.
    Rezailashkajani M; Roshandel D; Shafaee S; Zali MR
    Dig Liver Dis; 2008 Jun; 40(6):412-7. PubMed ID: 18342588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality of life measurement clarifies the cost-effectiveness of Helicobacter pylori eradication in peptic ulcer disease and uninvestigated dyspepsia.
    Groeneveld PW; Lieu TA; Fendrick AM; Hurley LB; Ackerson LM; Levin TR; Allison JE
    Am J Gastroenterol; 2001 Feb; 96(2):338-47. PubMed ID: 11232673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost analysis of a provincial drug program to guide the treatment of upper gastrointestinal disorders.
    Bursey F; Crowley M; Janes C; Turner CJ
    CMAJ; 2000 Mar; 162(6):817-23. PubMed ID: 10750472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.